Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 27,698 Shares

Posted by Geri Gentry on May 30th, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 27,698 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $0.46, for a total transaction of $12,741.08. Following the sale, the director owned 655,135 shares in the company, valued at approximately $301,362.10. This trade represents a 4.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $14,650.20.
On Wednesday, May 27th, Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.48, for a total transaction of $38,808.96.
On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total transaction of $31,936.50.
On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $39,341.25.
On Thursday, May 21st, Luke Evnin sold 36,387 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total transaction of $15,282.54.
On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.43, for a total transaction of $36,934.85.
On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $28,336.50.
On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.50, for a total transaction of $11,092.00.
On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $43,446.40.
On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total transaction of $22,745.16.

Werewolf Therapeutics Trading Down 1.3%

Shares of NASDAQ:HOWL opened at $0.45 on Friday. The firm’s 50 day moving average is $0.74 and its two-hundred day moving average is $0.75. Werewolf Therapeutics, Inc. has a 52 week low of $0.40 and a 52 week high of $2.38. The firm has a market capitalization of $21.87 million, a P/E ratio of -0.36 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. Analysts predict that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HOWL. Jane Street Group LLC acquired a new position in shares of Werewolf Therapeutics during the second quarter valued at approximately $409,000. Renaissance Technologies LLC increased its stake in shares of Werewolf Therapeutics by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after acquiring an additional 221,766 shares during the period. Citadel Advisors LLC acquired a new position in shares of Werewolf Therapeutics during the third quarter valued at approximately $304,000. Vanguard Group Inc. increased its stake in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after acquiring an additional 109,796 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Werewolf Therapeutics during the second quarter valued at approximately $113,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on HOWL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $3.75.

Get Our Latest Stock Analysis on HOWL

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.